Latest Sipuleucel-T Stories

2010-06-02 11:00:00

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that David C. Stump, M.D., has been elected to the Company's Board of Directors. Dr. Stump is currently executive vice president of research and development for Human Genome Sciences, Inc.

2010-05-31 13:00:00

SEATTLE and SAN FRANCISCO, May 31 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

2010-05-20 17:00:00

SEATTLE and CHICAGO, May 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Monday, June 7 at 8:00 a.m.

2010-05-10 16:33:00

SEATTLE, May 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009.

2010-05-05 10:18:00

SILVER SPRING, Md., May 5 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has approved a new treatment for certain men with advanced prostate cancer. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Called Provenge (sipuleucel-T), the treatment stimulates a patient's own immune system to respond against the cancer. Learn more about FDA's approval of Provenge at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm210620 Sign up for e-mail notices of new FDA...

2010-04-29 16:08:00

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA).

2010-04-29 12:55:00

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S.

2010-04-29 12:08:00

SILVER SPRING, Md., April 29 /PRNewswire-USNewswire/ -- The U.S.

2010-04-21 07:00:00

SEATTLE and WASHINGTON, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced the presentation of additional data from the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) clinical trial showing evidence of immune responses in patients treated with PROVENGE® (sipuleucel-T) and supporting its proposed mechanism of action.

2010-04-19 09:15:27

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

Word of the Day
  • Any of various tropical Old World birds of the family Indicatoridae, some species of which lead people or animals to the nests of wild honeybees. The birds eat the wax and larvae that remain after the nest has been destroyed for its honey.
Honeyguide birds have even been known to eat candles.